Morningstar

Zoetis Inc Class A ZTS

Morningstar Rating
Unlock
Stock XNYS Rating as of
$74.23 −1.10 (1.46%)
View Full Chart
As of Cboe BZX Real-Time Price Open

Company Report

View Archive

Zoetis' Wide Moat Remains Intact, but We've Lowered Our Fair Value Estimate

Debbie S. Wang

Zoetis is the undisputed leader in the global animal health industry, and we believe it possesses the widest moat of all the competitors. Zoetis has set itself apart based on the impressive innovation that shows up across its product portfolio, including a number of drugs for specific pet ailments such as separation anxiety. The firm has also sought to expand its presence into virtually every type of animal-related health market, including aquaculture and pet diagnostics.

Read Full Report

Price vs Fair Value

View History
ZTS is trading at a LOCK|mGY^#MX premium.
Price
$75.35
Fair Value
LOCK|>h
Uncertainty
LOCK|>b%^%
1-Star Price
LOCK|^R
5-Star Price
b@
Economic Moat
LOCK|!j
Capital Allocation
LOCK|$l@KtgL

Bulls Say, Bears Say

Bulls

Growing interest in probiotics, antibacterial peptides, and immune modulators as alternatives to antibiotics offers many targets for innovation.

Bears

Strict regulation or restriction of antibiotic use in animals could harm Zoetis' sales of production animal products.

Show More

News

View All

Articles & Videos

Trading Information

Previous Close Price
$75.35
Day Range
$74.05–76.02
52-Week Range
$71.48–160.49
Bid/Ask
$74.22 / $74.27
Shares Outstanding
419.23M
Market Cap
$31.10B
Volume/Avg
2M / 7M

Key Statistics

Price/Earnings (Normalized)
11.65
Price/Sales
3.47
Dividend Yield (Trailing)
2.77%
Dividend Yield (Forward)
2.81%
Total Yield
13.53%

Company Profile

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Value
Total Number of Employees
14,500
Website
https://www.zoetis.com

Competitors

Valuation

View More
Metric
ZTS
ELAN
SNY
Price/Earnings (Normalized)
 11.6526.0010.39
Price/Book Value
 9.801.961.26
Price/Sales
 3.472.591.94
Price/Cash Flow
 10.0125.188.90
Price/Earnings
ZTS
ELAN
SNY

Financial Strength

Metric
ZTS
ELAN
SNY
Quick Ratio
 1.680.950.20
Current Ratio
 3.152.161.01
Interest Coverage
 14.940.1711.82
Quick Ratio
ZTS
ELAN
SNY

Profitability

Metric
ZTS
ELAN
SNY
Return on Assets (Normalized)
 19.04%3.69%7.49%
Return on Equity (Normalized)
 65.55%7.49%13.70%
Return on Invested Capital (Normalized)
 24.10%6.35%10.47%
Return on Assets
ZTS
ELAN
SNY

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|?sW&J#tMLOCK|HYjlm$67B
 Haleon PLC ADR
HLN
LOCK|@^yr<kdLOCK|J#X$44B
 Teva Pharmaceutical Industries Ltd ADR
TEVA
LOCK|$#Xx&&dLOCK|$bqbQ$37B
 Viatris Inc
VTRS
LOCK|qw@r@DLOCK|dJz$20B
 Elanco Animal Health Inc
ELAN
LOCK|knLOCK|s^&$13B
 Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|!?<rms<LOCK|Ks&$10B
 Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|G<@^HgLOCK|&&T$8B
 Prestige Consumer Healthcare Inc
PBH
LOCK|Tpb%?C%LOCK|M>vR$2B
 Perrigo Co PLC
PRGO
LOCK|Z?HLRLLOCK|@v$1B

Sponsor Center